RPT-FEATURE-As Electronics Founders Singapore Turns To Drugs
Reuters, 11.14.03, 3:42 AM ET
By Jason Szep

SINGAPORE, Nov 14 (Reuters) - A bus, painted in futuristic swirls of green and blue, picks up scientists from
Singapore's top university and chugs past a row of ageing factories before dropping them off at a gleaming new
bioscience park.

The trip highlights a transition in Singapore's convalescing economy as policy makers gravitate towards biotechnology
and away from the electronics industry that catapulted the island from third world to first in three decades.

The free, air-conditioned ride to the Biopolis complex is also a reminder of the first-class treatment afforded the
nation's hottest new commodity -- scientists.

Singapore's success in remoulding its economy to one powered by research and exports of pharmaceuticals and medical
equipment, rather than hard disk drives and computer chips, hinges on how quickly it can lure and groom scientists.

China, India, South Korea, Australia, Malaysia and Taiwan are also pouring money into biotech, with varying degrees of
success.

"Singapore has been very, very quick moving in establishing an environment that is very favourable for biotech," said
Susan Ward, managing director of Health Resources International, a consultancy specialising in Asian healthcare.

Luring scientists and developing a niche focus is essential to Singapore's Biotech ambitions, Ward says, noting that
the island trailed China and India in biotech entrepreneurialism.

COURTING THE WORLD'S SCIENTISTS

Singapore accelerated its courtship of the world's scientific community this month with the opening of Biopolis, a
S$500 million ($288 million) high-tech neighbourhood of research facilities designed as a base for scientists and their
families.

The seven shiny buildings with space-age names such as Chromos and Proteos house a sprawling medical library, 500-seat
auditorium, lecture theatres, offices, cafes and a lab housing up to 200,000 mice bred for medical research.

To draw scientists and biotech funds into its 40,000-sq-metre (430,600-sq-ft) Biopolis park, Singapore is offering a
mix of tax breaks, grants other incentives worth $1.3 billion -- and one of the world's most relaxed legal climates for
research.

Facing fewer restrictions than in the United States or parts of Europe, scientists can clone human embryos and keep
them alive for 14 days in Singapore to produce stem cells -- master cells that can grow into almost any tissue in the
body.

This is fast turning Singapore into the world's capital for work on stem cells, which can be harvested from aborted
embryos, embryos left over from in-vitro fertilisation or embryos cloned for the purpose.

Alan Colman, who famously cloned "Dolly" the sheep, moved to Singapore last year when his European funding slowed.

Some scientists say stem cell research could yield a cure for Alzheimer's or Parkinson's disease, but the Catholic
Church believes destroying embryos is murder -- a position backed by U.S. President George W. Bush.

Steven Fang, chief of Cordlife Pte Ltd, which is involved in stem cell work, chose Singapore over Cambridge,
Massachusetts as his group headquarters after a merger with Cambridge-based Cytomatrix in April, drawn by a combination
of tax breaks, relaxed laws and its proximity to fast-growing China.

"We had a lengthy internal discussion over whether to base in Singapore or Cambridge," he said. "Our key investors were
from Asia, and that was another reason."

NICHE AMBITIONS

The potential for explosive biotech growth in China and India means forging a quick niche is essential, Philip Yeo, the
head of the government agency that runs Biopolis, told Reuters.

"We cannot compete with America. We cannot compete with Europe, so we look for areas where we have an advantage. An
advantage is that we are in Asia. We can develop a niche."

Singapore aims to double its biomedical output to S$20 billion by 2010, or about 12 percent of the island's economy,
and raise its share of manufacturing to 15 to 20 percent by 2005 from seven percent now, filling a gap left by
shrinking electronics.

Returns form electronics, the lifeblood of the economy, are now about 30 percent of total manufacturing, down from 50
percent five years ago, as cheaper Chinese exports take market share.

"To counter the cyclical nature of the electronics industry, Singapore will try as much as possible to throw their war
chest at companies to come here in as many sectors as possible," said Song Seng Wun, an economist at stockbroker GK
Goh.

"Biomedical is their glamorous sector at this point," said Song, but he noted it was not a major source of jobs.

Six of the world's top pharmaceutical companies operate in Singapore, including U.S.-based Pfizer Inc, the world's
largest, Merck & Co Inc, GlaxoSmithKline Plc and Schering-Plough Corp.

Economists suspect manufacturing of Pfizer's anti-impotency drug Viagra caused a surprise 10.3 percent rise in
Singapore's industrial production in August, which the government attributed almost entirely to pharmaceutical
production. (US$1=S$1.735)

SOURCE: Reuters News Service / Forbes
http://www.forbes.com/markets/newswire/2003/11/14/rtr1148092.html

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn